When: Weekly close below $141.50 on rising volume

Then: Exit position; 200 SMA break with conviction compromises long-term thesis

HOLD - Trim to 2-3% if above target weight; do not add new capital

• Price below 50 SMA at $150.77 and Bollinger midline at $151.73; 10 EMA has crossed below 50 SMA with expanding negative MACD histogram
• RSI at 47.79 is neutral; one session 2.8% bounce does not confirm reversal after six weeks of sustained selling pressure
• True downside if 200 SMA breaks is $130 zone (13% drawdown), not the cited 4.8% to $142.73
• Trailing EPS $4.57 vs forward consensus $7.25 represents 58% growth estimate; underlying organic growth only 15-20%
• Forward P/E of 20.7x expands to 23x if estimates cut just 10%, driving 5-8% multiple compression
• Goodwill of $27.65 billion is a live liability if automation capex slows or margins compress in higher-for-longer rate environment
• Net debt $11.57 billion, debt-to-equity 67.7%, current ratio below 1.0, working capital negative, cash only $1.54 billion against $13.76 billion total debt
• Interest coverage at 7x is not fortress-level given $11.57B net debt and dependency on continued strong FCF
• 10-year yield at 5% with 95% Polymarket odds of zero Fed cuts in 2026 compresses the 32.8x trailing P/E multiple
• EMR beta of 1.23 means 8-12% price reaction to earnings miss or in-line guidance; 40-60 bps impact on portfolio from 4-5% position
• 200 SMA at $142.73 is the critical support level; breaching opens downside toward $130 March-May base
• Q4 FY26 guidance remains untested with $128M restructuring charges in Q3 FY26

→ vs aggressive: Technical 'base-building' framing ignores price still below 50 SMA, Bollinger midline, and 10 EMA/50 SMA death cross; RSI neutral at 47.79 does not confirm reversal

→ vs aggressive: Risk/reward framing of 2:1 upside is flawed; true downside to $130 zone is 13%, not 4.8%, making it a coin flip with longer downside tail

→ vs aggressive: 58% EPS growth is consensus estimate comparing depressed TTM EPS $4.57 to forward $7.25; actual organic growth 15-20% and estimates get cut

→ vs aggressive: Goodwill dismissal is intellectually lazy; $27.65B impairment would crater reported earnings, trigger credit reviews, and force buyback/dividend pauses

→ vs aggressive: 7x interest coverage ignores $11.57B net debt, 67.7% debt/equity, negative working capital, and $1.54B cash against $13.76B total debt

→ vs aggressive: 20.7x forward P/E is not 'reasonable' when trailing is 32.8x in 5% yield environment with 95% odds of zero Fed cuts in 2026

→ vs aggressive: 4-5% position size is concentration risk; beta 1.23 means 8-12% earnings reaction creates 40-60 bps portfolio drag

HOLD at 2-3% target weight; do not add at current $149.92; pre-commit to scaled buys at $144-$146; define re-engagement trigger at $150.77

• Long-term uptrend intact: stock sitting $7 above 200 SMA at $142.73, not in structural breakdown
• Bounce volume to $149.92 was 3.8 million shares — described as institutional flow, not retail noise
• Q3 FY26 operating margin: 22.7% vs 19.6% prior year — described as genuine inflection
• Zacks Rank 2 upgrade noted as non-trivial signal
• Trailing P/E of 32.8x leaves thin margin for error
• Forward P/E of 20.7x described as reasonable multiple for a compounder with 15-20% growth and software-style margin expansion
• Goodwill at 66% of assets (post National Instruments deal) flagged as structural balance sheet feature
• Current ratio below 1 and negative working capital noted as liquidity flags
• 69 consecutive years of dividend increases; yield above 1.5% described as scarcity asset in 5% ten-year environment
• MACD histogram expanding negative for six weeks while 10 EMA below 50 SMA signals institutional distribution
• Base case: continued range-bound chop between $145 and $153
• Target weight: 2-3% (trim if currently above 3-4%)
• Pre-committed buy zone: $144 to $146 scaled 1% at a time across 2-3 sessions
• Hard stop at $142.73 — downside per tranche roughly 2.5%
• Re-engagement trigger: close above $150.77 on above-average volume for two consecutive sessions
• Pause trigger: close below $145.83 on rising volume
• Upside scenario if base resolves bullishly: 9-14%
• Beta of 1.23 amplifies tape; earnings-day volatility risk elevated
• Ten-year at 5% with 45% odds of pushing to 5.20% by year-end
• Dual exposure: defensive bid from yield-seeking capital AND automation/AI capex demand justifies holding

→ vs aggressive: Concentration risk into untested earnings print is the bigger danger, not opportunity cost of missing 5% upside; scaling to 4-5% is not capitulation but imprudent risk-taking

→ vs aggressive: Anchoring downside to 200 SMA at $142.73 ignores tail risk; 200 SMA breaking on rising volume opens measured move toward $130 with non-trivial probability

→ vs aggressive: MACD histogram expanding negative for six weeks with 10 EMA below 50 SMA indicates institutional distribution, not accumulation; one volume day doesn't erase that pattern

→ vs conservative: Dismissal of 20.7x forward P/E misses the point — markets price forward, and consensus 7.25 EPS justifies reasonable multiple for quality compounder

→ vs conservative: Dividend king framing as mere defensive ballast underweights its role as a scarcity asset attracting income-oriented institutional rotation

→ vs conservative: Overcorrected into roughly 50-50 probability stack; base case is range-bound chop ($145-$153), not full breakdown

→ vs conservative: Industrial compounder argument ignores EMR's recurring-revenue-like earnings stream giving it software-style duration characteristics